Non-coding polymorphisms in nucleotide binding domain 1 in ABCC1 gene associate with transcript level and survival of patients with breast cancer

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Kunická, Tereza ^a,b   Václavíková, Radka ^a   Hlaváč, Viktor ^a,b   Vrána, David ^a,c   Pecha, Václav ^d   Rauš, Karel ^d   Trnková, Markéta ^e   Kubáčková, Kateřina ^f   Ambruš, Miloslav ^g   Vodičková, Ludmila ^a,h   Vodička, Pavel ^b,h   Souček, Pavel ^a  

^a NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

^d INSTITUTE FOR THE CARE OF MOTHER AND CHILD   (Czech Republic)

^e Biolab Praha   (Czech Republic)

^f UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

^h INSTITUTE OF EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; TAXANE DERIVATIVE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ABCC1 GENE; ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE BINDING DOMAIN 1; PROTEIN DOMAIN; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BREAST TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; SURVIVAL;

AGED; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RNA, MESSENGER; SURVIVAL ANALYSIS;

EID: 84905389396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101740     Document Type: Article

References (49)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al (2010) GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 (Internet). Lyon, France: International Agency for Research on Cancer, http://globocan.iarc.fr.
2. Biedler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30: 1174-1184.
3. Szakacs G, Annereau JP, Lababidi S, Shankavaram U, Arciello A, et al (2004) Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells. Cancer Cell 6: 129-137. (Pubitemid 39485685)
4. Ferguson LR, De Flora S (2005) Multiple drug resistance, antimutagenesis and anticarcinogenesis. Mutat Res 591: 24-33. (Pubitemid 41654837)
5. Liscovitch M, Lavie Y (2002) Cancer multidrug resistance: a review of recent drug discovery research. IDrugs 5: 349-355. (Pubitemid 38133051)
6. Thomas H, Coley HM (2003) Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control 10: 159-165. (Pubitemid 36437822)
7. Akan I, Akan S, Akca H, Savas B, Ozben T (2005) Multidrug resistance-associated protein 1 (MRP1) mediated vincristine resistance: effects of N-acetylcysteine and Buthionine sulfoximine. Cancer Cell International 5: 22.
8. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258: 1650-1654. (Pubitemid 23012438)
9. Grant CE, Kurz EU, Cole SP, Deeley RG (1997) Analysis of the intron-exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics 45: 368-378.
10. Cole SP (2014). Targeting Multidrug Resistance Protein 1 (MRP1, ABCC1): Past, Present, and Future. Annu Rev Pharmacol Toxicol 54: 95-117.
11. Hipfner DR, Deeley RG, Cole SP (1999) Structural, mechanistic and clinical aspects of MRP1. Biochim Biophys Acta 1461: 359-376.
12. Yamada A, Ishikawa T, Ota I, Kimura M, Shimizu D, et al (2013) High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival. Breast Cancer Res Treat 137: 773-782.
13. Hlaváč V, Brynychová V, Václaví ková R, Ehrlichová M, Vrána D, et al (2013) The expression profile of ABC transporter genes in breast carcinoma. Pharmacogenomics 14: 515-529.
14. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, et al (2001) Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46: 656-663. (Pubitemid 33134743)
15. Oselin K, Mrozikiewicz PM, Gaikovitch E, Pahkla R, Roots I (2003) Frequency of MRP1 genetic polymorphisms and their functional significance in Caucasians: detection of a novel mutation G816A in the human MRP1 gene. Eur J Clin Pharmacol 59: 347-350. (Pubitemid 37100355)
16. Wang Z, Wang B, Tang K, Lee EJD, Chong SS, et al (2005) A functional polymorphism within the MRP1 gene locus identified through its genomic signature of positive selection. Hum Mol Genet 14: 2075-2087. (Pubitemid 41418043)
17. Vulsteke C, Lambrechts D, Dieudonné A, Hatse S, Brouwers B, et al (2013) Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving neoadjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC). Ann Oncol 24: 1513-1525.
18. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, et al (2002) A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12: 321-330. (Pubitemid 34620660)
19. Leslie EM, Létourneau IJ, Deeley RG, Cole SP (2003) Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42: 5214-5224. (Pubitemid 36560417)
20. Yin J-Y, Huang Q, Yang Y, Zhang J-T, Zhong M-Z, et al (2009) Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population. Pharmacogenet Genomics 19: 206-216.
21. Brynychová V, Hlaváč V, Ehrlichová M, Václavíková R, Pecha V, et al (2013) Importance of transcript levels of caspase-2 isoforms S and L for breast carcinoma progression. Future Oncol 9: 427-438.
22. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22: 1736-1747.
23. Topic E, Gluhak J (1991) Isolation of restrictible DNA. Eur J Clin Chem Clin Biochem 29: 327-330.
24. Barrett JC, Fry B, Maller J, Daly MJ (2005) Haploview: analysis and visualization of LD and haplotype maps Bioinformatics 21: 263-265. (Pubitemid 40202029)
25. Untergrasser A, Cutcutache I, Koressaar T, Ye J, Faircloth BC, et al (2012) Primer3 - new capabilities and interfaces. Nucleic Acids Res 40: e115.
26. Soucek P, Anzenbacher P, Skoumalova I, Dvorak M (2005) Expression of cytochrome P450 genes in CD34+ hematopoietic stem and progenitor cells. Stem Cells 23: 1417-1422. (Pubitemid 41504929)
27. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55: 611-622.
28. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, et al (2002) The structure of haplotype blocks in the human genome. Science 296: 2225-2229. (Pubitemid 34680308)
29. Benjamini Y, Hochberg Y (1995) Controlling the False Discovery Rate: A practical and powerful approach to multiple testing. Journal of the Royal Statistical Society B 57: 289-300.
30. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234. (Pubitemid 43336035)
31. Gao M, Cui HR, Loe DW, Grant CE, Almquist KC, et al (2000) Comparison of the functional characteristics of the nucleotide binding domains of multidrug resistance protein 1. J Biol Chem 275: 13098-13108. (Pubitemid 30241472)
32. Qin L, Zheng J, Grant CE, Jia Z, Cole SP, et al (2008) Residues responsible for the asymmetric function of the nucleotide binding domains of multidrug resistance protein 1. Biochemistry 47: 13952-13965.
33. Iram SH, Cole SP (2011) Expression and function of human MRP1 (ABCC1) is dependent on amino acids in cytoplasmic loop 5 and its interface with nucleotide binding domain 2. J Biol Chem 286: 7202-7213.
34. Ramaen O, Leulliot N, Sizun C, Ulryck N, Pamlard O, et al (2006) Structure of the human multidrug resistance protein 1 nucleotide binding domain 1 bound to Mg2+/ATP reveals a non-productive catalytic site. J Mol Biol 359: 940-949. (Pubitemid 43831921)
35. Rungsardthong K, Mares-Sámano S, Penny J (2012) Virtual screening of ABCC1 transporter nucleotidebinding domains as a therapeutic target in multidrug resistant cancer. Bioinformation 8: 907-911.
36. Vaclavikova R, Nordgard SH, Alnaes GIG, Hubackova M, Kubala E, et al (2008) Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients. Pharmacogenet Genomics 18: 263-273. (Pubitemid 351323241)
37. Kim B, Fatayer H, Hanby AM, Horgan K, Perry SL, et al (2013) Neoadjuvant Chemotherapy Induces Expression Levels of Breast Cancer Resistance Protein That Predict Disease-Free Survival in Breast Cancer. PLoS ONE 8: e62766.
38. Filipits M, Pohl G, Rudas M, Dietze O, Lax S, et al (2005) Clinical role of multidrug resistance protein 1 expression in chemotherapy resistance in early-stage breast cancer: the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 23: 1161-1168. (Pubitemid 46202272)
39. McDonagh EM, Whirl-Carrillo M, Garten Y, Altman RB, Klein TE (2011) From pharmacogenomic knowledge acquisition to clinical applications: the PharmGKB as a clinical pharmacogenomic biomarker resource. Biomark Med 5: 795-806.
40. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, et al (2011) Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 21: 440-446.
41. Teft WA, Mansell SE, Kim RB (2011) Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1). Drug Metab. Dispos 39: 558-562.
42. Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H (2012) Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab Pharmacokinet 27: 122-131.
43. Lips EH, Mulder L, de Ronde JJ, Mandjes IA, Koolen BB, et al (2013) Breast cancer subtyping by immunohistochemistry and histological grade outperforms breast cancer intrinsic subtypes in predicting neoadjuvant chemotherapy response. Breast Cancer Res Treat 140: 63-71.
44. Letourneau IJ, Deeley RG, Cole SP (2005) Functional characterization of non-synonymous single nucleotide polymorphisms in the gene encoding human multidrug resistance protein 1 (MRP1/ABCC1). Pharmacogenet Genomics 15: 647-657. (Pubitemid 41113337)
45. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al (2010) A method and server for predicting damaging missense mutations. Nat Methods 7: 248-249.
46. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4: 1073-1081.
47. Boyle AP, Hong EL, Hariharan M, Cheng Y, Schaub MA, et al (2012) Annotation of functional variation in personal genomes using RegulomeDB. Genome Res 22: 1790-1797.
48. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, et al (2005) Mapping determinants of human gene expression by regional and genome-wide association. Nature 437: 1365-1369. (Pubitemid 41568683)
49. Marchler-Bauer A, Lu S, Anderson JB, Chitsaz F, Derbyshire MK, et al (2011) CDD: a Conserved Domain Database for the functional annotation of proteins. Nucleic Acids Res 39: D225-229.